Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 11 Best All-Time Low Stocks to Buy According to Analysts. On July ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The global Enzyme Replacement Therapy (ERT) market is poised for significant expansion, projected to reach USD 21.62 billion ...